Gliclazide tablets, the latest anti-diabetic drug has been given a nod by China’s SFDA and will be commercially available from July this year. This drug is manufactured by Tianyin Pharmaceutical Co. Inc. the company has its expertise in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals.
Gliclazide is an oral anti-diabetic medication which is prescribed for the patients of diabetes mellitus who are not able to manage their diabetes by appropriate diet plan, exercise and insulin therapy. The drug is classified as a sulfonylurea and is marketed as Glyloc and Reclide in India and Diamicron in Canada.
Gliclazide is used for treating hyperglycemia in gliclazide-responsive diabetes of stable, mild, non-ketosis prone, maturity-onset or adult type. Diabetes Mellitus is linked with high blood sugar, lack of insulin production or the health issue when the cells in the body stop creating insulin. The new treatment through Gliclazide will help patients control and manage diabetes. The main causes for diabetes includes unhealthy lifestyle, obesity and lack of physical activity.
hello
help me pleas
i am a diabetic man & fbs test =184 & a1c test=7 my doctor sima hashemi poor
in iran qazvin city malek abad street alley mirmiran-hariri -number 10
my country no match gliclazide 20 pleas send me original tablets with price
tank & by